Supported cancer types

IndiTreat® is for cancer therapy selection

With IndiTreat®, you can test different panels of drugs and drug combinations on microtumors derived from individual patients to identify resistance and sensitivity.

IndiTreat® CE IVD Colorectal Cancer Test

A method of determining which drugs offer the most suitable therapies for different patients with stage III–IV colorectal cancer, this test can be used before:

  • Postoperative adjuvant therapy
  • Neoadjuvant therapy
  • 1st and 2nd line therapy of metastatic disease
  • Therapy of end-stage metastatic patients
  • HIPEC (hyperthermic intraperitoneal chemotherapy)

IndiTreat® Ovarian Cancer Test

This test indicates which panels offer the most suitable therapies for different patients with ovarian cancer. Multi-center clinical validation trials are ongoing. This test is used before:

  • Postoperative adjuvant therapy
  • Neoadjuvant therapy
  • Therapy of recurrence regardless of previous platinum response
  • Selection of the most effective PARP-inhibitor in BRCA-mt patients
  • Selection of BRCA-wt patients who shall benefit from PARP-inhibition
  • Therapy of end-stage patients

IndiTreat® Pancreatic Cancer Test

A method of determining which drugs offer the most suitable therapies for different patients with pancreatic cancer. Multi-center clinical validation trials are ongoing. This test is used before:

  • Postoperative adjuvant therapy
  • Neoadjuvant therapy if a pancreatic biopsy is feasible
  • 1st and 2nd line palliative therapy

Want to know more?

Want to know more?

Contact us

Please contact 2cureX for more information

Email: info@2cureX.com
Phone: +45 22115399
Web: www.IndiTreat.com

Upcoming events

February 25, 2021

Year-End Report 2020

View previous reports

March 2, 2021

Nordnet Online Event

Read more

March 4, 2021

RedEye Investor Forum Online

Read more

March 16, 2021

CEO meets young investors, link to event will follow

Read more

Key benefits of IndiTreat

  • Tumor resistance
    Predict tumor resistance and sensitivity to cancer drugs
  • Right cancer treatment
    Select the most appropriate treatment, in accordance with guidelines or off-label
  • Better patient outcome
    Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
  • Help chemo-naïve CRC patients
    Identify the most effective treatment in chemo-naïve colorectal cancer patients
  • Help late-stage CRC patients
    Identify the most effective treatment in late-stage colorectal cancer patients
  • Functional precision medicine
    Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs